Maitreya Medicare Ltd

Maitreya Medicare Ltd maintains a conservative capital structure, with a debt-to-equity ratio of 0.16, significantly below the industry median of 0.45, indicating a low reliance on debt financing. The company’s liquidity position is moderate, with a current ratio of 2.58, suggesting it can cover short-term obligations but with limited excess capacity. Free cash flow of INR 9.33 million in the latest period reflects modest cash generation, though capital expenditures of INR -23.81 million indicate ongoing investment in infrastructure or equipment. Profitability metrics show a return on equity (ROE) of 5.84% and a return on assets (ROA) of 3.9%, both below the industry median of 7.2% and 5.1%, respectively. This suggests underperformance in asset utilization and equity returns compared to peers. Operating income of INR 34.40 million on revenue of INR 466.62 million yields a 7.37% margin, which is in line with the industry median of 7.5%. The company’s revenue is concentrated in India, with no disclosed international operations, and it operates a single hospital facility with 125 beds. No segmental breakdown is available, but the focus on multispecialty care implies a diversified service offering within a single geographic location. Revenue growth has not been explicitly disclosed, but the company’s operating cash flow of INR 50.57 million and free cash flow of INR 9.33 million suggest stable, albeit modest, cash generation. The outlook for the current fiscal year is neutral, with no significant revenue acceleration or contraction indicated in the data. Risk factors include moderate liquidity risk due to a current ratio of 2.58 and a negative net cash position after subtracting total debt. Dilution risk is low, with no recent share issuance or shelf registration disclosed. The company’s capital structure remains stable, with no material adjustments to valuation metrics in the latest period. Recent filings and transcripts are not available in the provided data, so no specific events can be cited. However, the company’s focus on critical care and super-specialty services may position it to benefit from long-term demographic trends in India’s healthcare sector.